Search research articles
Contact Us
Filters
Showing results (141-150 of 193) with videos related to
Page
of 20
Sort By:
Schweizerische Medizinische Wochenschrift
|
August 16, 1980
[Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71]
H J Senn, D Lei, A Castaño-Almendral, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 1, 1993
"Fatigue and malaise" as a quality-of-life indicator in small-cell lung cancer patients. The Swiss Group for Clinical Cancer Research (SAKK)
C Hürny, J Bernhard, R Joss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2013
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, E P Winer, A S Coates, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2003
The process of metastasisation for breast cancer
J Engel, R Eckel, J Kerr, et al.
Journal of Medicinal Chemistry
|
March 20, 1992
(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate
B Kohl, E Sturm, J Senn-Bilfinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2006
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
A Glaus, Ch Boehme, B Thürlimann, et al.
Schweizerische Medizinische Wochenschrift
|
March 22, 1986
[Malignant pericardial effusion--a sign of unfavorable prognosis?]
E E Holdener, D H Ryser, K Schaermeli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 1994
Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK)
R A Joss, P Alberto, E A Bleher, et al.
The Journal of Biological Chemistry
|
February 1, 2003
Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes
Joseph J Senn, Peter J Klover, Irena A Nowak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1997
Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82
H J Senn, R Maibach, M Castiglione, et al.
Page
of 20
Search research articles
Search
Showing results (141-150 of 193) with videos related to
Sort By:
Page
of 20
Schweizerische Medizinische Wochenschrift
|
August 16, 1980
[Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71]
H J Senn, D Lei, A Castaño-Almendral, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 1, 1993
"Fatigue and malaise" as a quality-of-life indicator in small-cell lung cancer patients. The Swiss Group for Clinical Cancer Research (SAKK)
C Hürny, J Bernhard, R Joss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2013
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, E P Winer, A S Coates, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2003
The process of metastasisation for breast cancer
J Engel, R Eckel, J Kerr, et al.
Journal of Medicinal Chemistry
|
March 20, 1992
(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate
B Kohl, E Sturm, J Senn-Bilfinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2006
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
A Glaus, Ch Boehme, B Thürlimann, et al.
Schweizerische Medizinische Wochenschrift
|
March 22, 1986
[Malignant pericardial effusion--a sign of unfavorable prognosis?]
E E Holdener, D H Ryser, K Schaermeli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 1994
Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK)
R A Joss, P Alberto, E A Bleher, et al.
The Journal of Biological Chemistry
|
February 1, 2003
Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes
Joseph J Senn, Peter J Klover, Irena A Nowak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1997
Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82
H J Senn, R Maibach, M Castiglione, et al.
Page
of 20